KEEPER-SECURITY
9.7.2021 09:02:08 CEST | Business Wire | Press release
UK businesses are struggling to deal with multiple urgent cybersecurity challenges, new research by Keeper Security has revealed. The 2021 Cybersecurity Census Report shows cyberattacks are becoming more vicious, frequent and sophisticated, while UK businesses are underprepared and too slow to counter these attacks. As a result, senior leaders within UK organisations are preoccupied with playing a cyberattack blame game instead of investing in boosting their defences.
The report has found that more than nine in ten (92%) UK business suffered a cyberattack in the last 12 months and three quarters (78%) feel unprepared to deal with this threat. Nearly a third (31%) believe CTOs should take the blame in the case of a successful cyberattack. Such a weight of responsibility means cybersecurity standards are dropping: 36% of senior IT leaders confess to having kept a cyberattack to themselves, while 32% admit to using weak credentials such as ‘password’ or ‘admin’ to protect their data.
“UK businesses are clearly worried about their cybersecurity and, as our report has found, the challenges are manifold, affecting everything from budgets to productivity,” said Darren Guccione, CEO & co-founder, Keeper Security. “While there is a desire to boost security efforts, companies are facing many competing challenges right now and, understandably, might not always make cybersecurity investments a priority. Our report is an urgent reminder for organisations to proactively address their cybersecurity challenges as a priority since deferring them will make the consequences far more severe.”
Key findings include:
- Almost all (92%) UK organisations are aware of gaps or weak links in their cybersecurity defences are, but less than half (40%) are actively addressing all of them
- Two-thirds (66%) of UK organisations have relaxed their cybersecurity policies over the past 12 months so staff can work remotely or in order not to stifle productivity
- 58% of IT professionals feel employees at their organisations do not understand the full consequences of poor cyber-hygiene
- 61% of UK companies have a skills shortage in cybersecurity
- The financial fallout of cyberattacks has been damaging, too, costing nearly one in ten (8%) UK businesses over £1 million
- An overwhelming 87% of IT leaders support the creation of a nationwide governing body to hold businesses to account when it comes to best online security practices
- And almost all (91%) are in agreement that UK businesses should be legally required to have basic cybersecurity protections in place to be allowed to operate
“Companies are struggling to put the right solutions in place to cope with cyberattacks and the consequences are both damaging and costly,” said Craig Lurey, CTO and co-founder, Keeper Security. “The conditions caused by Covid-19 have led to an increased amount of hybrid working, making effective cybersecurity defences even harder to achieve. But if businesses want to bounce back fully after the pandemic, they must get their security hygiene in order without delay.”
Despite the rise in cyberattacks and increasing pressures felt by security teams, more than a quarter of UK companies (28%) do not consider IT to be even in their top three priorities as they plan for the next 12 months. This is particularly worrying, given almost all (92%) UK organisations know where the gaps or weak links in their cybersecurity defences are but well under half (40%) are actively addressing them.
Guccione concludes: “While this situation can't be rectified overnight, there are straightforward steps UK businesses can take to boost their cyber defences. First, organisations should do a comprehensive cybersecurity audit, looking at where the gaps lie and how they can be addressed. Next, they need to put in place a clear plan of action for how to address these challenges. Running cybersecurity training sessions to educate employees and introducing a password management platform to keep credentials safe and secure are two simple, yet highly effective actions business can take today, to be better prepared against cyberattacks tomorrow.”
+++ ENDS +++
About Keeper Security Inc.
Keeper Security, Inc. (Keeper) is the highly-rated and patented cybersecurity platform for preventing password-related data breaches and cyberthreats. Keeper’s zero-knowledge security and encryption software is trusted by millions of people and thousands of businesses across the globe to mitigate the risk of cybertheft, boost employee productivity and meet compliance standards. Keeper has been named PC Magazine’s Best Password Manager of the Year & Editors’ Choice, PCWorld’s Editors’ Choice and is the winner of four G2 Best Software Awards and the InfoSec Award for Best Product in Password Management for SMB Cybersecurity. Keeper is SOC-2 and ISO 27001 Certified and is also listed for use by the U.S. federal government through the System for Award Management (SAM). Learn more at https://keepersecurity.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210709005049/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
